Published Manuscripts (2012)
, Curtis BH, . A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. J Med Econ 2012.
, Jendle J, Saraheimo M, Thorsteinsson B, , Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine 2012; 29(3): 303-12.
Davies MJ, Chubb BD, Smith IC, . Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Medicine 2012; 29(3): 313-20.
Published Manuscripts (2011)
, Aagren M, Haglund M, Ericsson A, Gschwend MH. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 2011; 39(1): 79-87.
, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clinical Therapeutics 2011; 33(11): 1698-712.
Lippuner K, , , Meury T, . A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 2011; 9(6): 403-17.
Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, , Dilla T. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinologia y Nutricion 2011; 58(7): 331-340.
, Erny-Albrecht KM, Kalsekar A, Bruhn D, . Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Current Diabetes Reviews 2011; 7(1): 61-74.
, , Pilgaard T, Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. Journal of Medical Economics 2011; 14(1): 36-46.
Published Manuscripts (2010)
Palmer JL, Beaudet A, White J, Plun-Favreau J, . Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in Therapy 2010; 27(11): 814-27.
, , Goodall G, Brändle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents: A long-term modelling study in Switzerland. Swiss Medical Weekly 2010; 140: w13103.
, Curtis BH, Boye KS, Goodall G, Pillemer SR. Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine 2010; 27(2): 189-96.
, , Plun-Favreau J, White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 2010; 26(6): 1399-412.
Published Manuscripts (2009)
Mittendorf T, , Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obesity and Metabolism 2009; 11(11): 1068-79.
Lee KH, Seo SJ, , Palmer JL, White J, . Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 2009; 12(Suppl 3): S55-S61.
, Kalsekar A, Boye K and Goodall G. The Impact of Obesity on Adverse Cardiovascular Outcomes in the General Population and in Patients with Type 2 Diabetes. Clinical Medicine, Endocrinology and Diabetes 2009; 2: 43-69.
Goodall G, Sarpong EM, Hayes C, . The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocrine Disorders 2009; 5: 9-19.
Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, . An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. Diabetic Medicine 2009; 26(8): 803-14.
Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P and . Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International Journal of Clinical Pharmacology and Therapeutics 2009; 47(8): 501-515.
Gschwend MG, Aagren M, . Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 2009; 12(2): 114-123.
Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, . Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Effectiveness and Resource Allocation 2009; 7(1): 9.
Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, . Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Medical Weekly 2009; 139(11-12): 173-84.
Published Manuscripts (2008)
Gaede P, , Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study. Diabetes Care 2008; 31(8): 1510-5
Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, . Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in Therapy 2008; 25(8): 752-74
, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value in Health 2008; 12(1): 1-9
, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Advances in Therapy 2008; 25(6): 567-84
Palmer JL, Goodall G, Nielsen S, Kotchie RW, , Palmer AJ, Roze S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion 2008; 24(5): 1417-28
Ray JA, Borker R, Barber B, , Belozeroff V, Palmer AJ. Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA. Value in Health 2008; 11(5): 800-8
Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, , Palmer AJ. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value in Health 2008; 11(S1): S43-51
Goodall G, Jendle JH, , Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice 2008; 62(6): 869-76
Minshall ME, Oglesby AK, Wintle ME, , Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value in Health 2008; 11(1): 22-33
Palmer AJ, , Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation 2008; 23(4): 1216-23
Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, . Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008; 11(4): 651-670.
Published Manuscripts (2007)
, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabetic Medicine 2007; 24(9): 982-1002
Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, , Palmer AJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007; 25(10): 881-97
Gilmer TP, Roze S, , Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ. Cost-effectiveness of diabetes case management for low-income populations. Health Services Research 2007; 42(5): 1943-59
Palmer AJ, , Ray JA. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. International Journal of Clinical Practice 2007; 61(10): 1626-33
Ray JA, Boye KS, Yurgin N, , Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research and Opinion 2007; 23(3): 609-22
, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Advances in Therapy 2007; 24(2): 273-90
Palmer AJ, , Ray JA, Roze S, Muszbek N. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. European Journal of Health Economics 2007; 8(2): 161-68
Ray JA, , Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes, Obesity and Metabolism 2007; 9(1): 103-13
Palmer AJ, , Ray JA, Foos V, Lurati F, Smith I, Lammert M, Roze S. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Current Medical Research and Opinion 2007; 23(4): 895-901
Published Manuscripts (2006)
, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. International Journal of Clinical Practice 2006; 60(9): 1138-45
Palmer AJ, , Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de ZD, Parving HH, Laville M. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Current Medical Research and Opinion 2006; 22(11): 2095-100
Palmer AJ, Roze S, , Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brandle M. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Medical Weekly 2006; 136(21): 346-52
Tucker DM, Palmer AJ, , Roze S, Ray JA. Counting the costs of overweight and obesity: modeling clinical and cost outcomes. Current Medical Research and Opinion 2006; 22(3): 346-52
, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Advances in Therapy 2006; 23(2): 191-207
Roze S, , Evers T, Palmer AJ. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Current Medical Research and Opinion 2006; 22(7): 1415-24
Palmer AJ, Chen R, , Roze S, Bregman B, Mehin N, Gabriel S. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes and Metabolism 2006; 32(1): 69-76
Palmer AJ, Roze S, Rodby RA, , Ritz E, Lehnert H. Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy. Deutsche Medizinische Wochenschrift 2006; 131(31): 1721-6
Published Manuscripts (2005)
, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Current Medical Research and Opinion 2005; 21(12): 2063-71
Roze S, , Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine 2005; 22(9): 1239-45
Ray JA, , Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Current Medical Research and Opinion 2005; 21(10): 1617-29
Minshall ME, Roze S, Palmer AJ, , Foos V, Ray J, Graham C. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clinical Therapeutics 2005; 27(6): 940-50
Palmer AJ, Tucker DM, , Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrology Dialysis Transplantation 2005; 20(6): 1103-9
Palmer AJ, , Roze S, Lammert M, Spiesser J, Gabriel S. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. Current Medical Research and Opinion 2005; 21(1): 19-26
Published Manuscripts (2004)
Palmer AJ, Roze S, , Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Current Medical Research and Opinion 2004; 20(11): 1729-46
Palmer AJ, Roze S, , Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004; 20(S1): S5-26
Palmer AJ, Roze S, , Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Medical Research and Opinion 2004; 20(S1): S27-40
Palmer AJ, Roze S, Lammert M, , Minshall ME, Nicklasson L, Gall MA, Spinas GA. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research and Opinion 2004; 20(S1): S41-51
Palmer AJ, Roze S, , Minshall ME, Hayes C, Oglesby A, Spinas GA. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Current Medical Research and Opinion 2004; 20(S1): S52-58
Palmer AJ, Roze S, , Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. Current Medical Research and Opinion 2004; 20(S1): S59-66
Palmer AJ, Roze S, , Minshall ME, Lammert M, Nicklasson L, Spinas GA. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Current Medical Research and Opinion 2004; 20(S1): S67-73
Palmer AJ, Roze S, , Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical Therapeutics 2004; 26(2): 304-21
Dial with SkypeOut